Key Insights

Highlights

Success Rate

60% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 60/100

Termination Rate

12.9%

4 terminated out of 31 trials

Success Rate

60.0%

-26.5% vs benchmark

Late-Stage Pipeline

10%

3 trials in Phase 3/4

Results Transparency

67%

4 of 6 completed with results

Key Signals

4 with results60% success

Data Visualizations

Phase Distribution

25Total
Not Applicable (3)
Early P 1 (2)
P 1 (8)
P 2 (9)
P 3 (3)

Trial Status

Recruiting7
Completed6
Not Yet Recruiting6
Unknown5
Terminated4
Active Not Recruiting3

Trial Success Rate

60.0%

Benchmark: 86.5%

Based on 6 completed trials

Clinical Trials (31)

Showing 20 of 20 trials
NCT07572669Phase 2Recruiting

Moxibustion for Steroid-Refractory Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

NCT06936566Phase 2RecruitingPrimary

MAGIC Ruxolitinib for aGVHD

NCT02611180Active Not RecruitingPrimary

Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease

NCT07070674Phase 1RecruitingPrimary

A Phase Ib Clinical Study of AC-003 Capsules in Subjects With aGVHD.

NCT06294678Phase 3Active Not RecruitingPrimary

Effect of Stem Cell Infusion Time on aGVHD in Patients With Hematological Malignancies

NCT03721965Phase 1TerminatedPrimary

Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric Subjects

NCT07188909Not ApplicableNot Yet RecruitingPrimary

Clinical Observation on the Efficacy of Patient-Donor Derived Probiotics in Improving Intestinal Flora Disorder in Patients With Intestinal Acute Graft-Versus-Host Disease (aGVHD)

NCT06880419Phase 2RecruitingPrimary

Anti-CD25 rhMAb for aGVHD Prevention in High-Risk Adults Using the daGOAT Model

NCT06294691Phase 3RecruitingPrimary

Effect of Stem Cell Infusion Time on aGVHD in Patients With Nonmalignant Hematologic Diseases

NCT05673876Phase 1CompletedPrimary

A Study to Assess the Safety and Pharmacokinetics of GDC-8264 in Combination With Standard of Care in Participants With Acute Graft-Versus-Host Disease (aGVHD)

NCT06949267Early Phase 1Not Yet RecruitingPrimary

A Study of iMSC for the Prevention of Acute Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

NCT06941350Phase 1Not Yet RecruitingPrimary

A Trial to Evaluate the Safety and Efficacy of NCR102 in Subjects With aGVHD

NCT01521039CompletedPrimary

Assessment of MicroRNA Expression in Acute Graft-versus-Host Disease

NCT06750133Phase 1RecruitingPrimary

Universal CNK-UT Therapy for Refractory aGVHD

NCT06708507RecruitingPrimary

Tissue-resident Immune Cell Subsets in aGVHD

NCT06593834Not ApplicableNot Yet RecruitingPrimary

A Clinical Study of Bacillus Coagulans in Acute Graft-Versus-Host Disease After Hematopoietic Stem Cell Transplantation

NCT06490562Not ApplicableNot Yet RecruitingPrimary

Low-dose Cyclophosphamide or CNI in the Prevention of Acute Graft-versus-host Disease After gDLI

NCT06394895Active Not RecruitingPrimary

Donor Neutrophil Subsets to Predict the Risk of aGVHD

NCT04539470Phase 1CompletedPrimary

Study to Evaluate the Safety and Pharmacokinetics of Efmarodocokin Alfa in Combination With Standard of Care in Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

NCT04971551Phase 2Not Yet RecruitingPrimary

A Study of Jaktinib for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease.

Scroll to load more

Research Network

Activity Timeline